<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">17635499</PMID>
        <DateCompleted>
            <Year>2008</Year>
            <Month>02</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1365-2125</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>64</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>British journal of clinical pharmacology</Title>
                <ISOAbbreviation>Br J Clin Pharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The pharmacokinetic profile of sitaxsentan, a selective endothelin receptor antagonist, in varying degrees of renal impairment.</ArticleTitle>
            <Pagination>
                <MedlinePgn>733-7</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">To investigate the pharmacokinetic profile of a single 100-mg oral dose of sitaxsentan, a selective endothelin type A receptor antagonist, in subjects with normal and impaired renal function.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">This was an open label, single oral dose study in subjects with normal [creatinine clearance (CrCL) &gt; or = 80 ml min(-1)] and impaired renal function (mild renal impairment CrCL 51-80 ml min(-1), moderate impairment CrCL 31-50 ml min(-1), severe impairment CrCL &lt; or = 30 ml min(-1)). All subjects received a dose of 100 mg sitaxsentan.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-four subjects were enrolled, six in each of the normal and three renal impairment groups. The mean plasma sitaxsentan concentrations were comparable across the groups, as were the mean values for C(max) (10.3-13.9 microg ml(-1)), AUC(infinity) (18.7-22.5 h microg(-1) ml(-1)), oral clearance (CL/F, 82.3-94.9 ml min(-1)), volume of distribution (Vz/F, 64.8-69.6 l) and elimination half-life (t(1/2), 8.6-9.6 h). There was substantial overlap among the four groups in the individual subject values for CL/F and Vz/F and no relationship between either of these parameters and CrCL.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">After a single 100-mg oral dose of sitaxsentan there were no differences in its pharmacokinetics among subjects with normal or impaired renal function.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Dhaun</LastName>
                    <ForeName>Neeraj</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Pharmacology Unit, University of Edinburgh, Queen's Medical Research Unit, Edinburgh, UK. bean.dhaun@ed.ac.uk</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Melville</LastName>
                    <ForeName>Vanessa</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kramer</LastName>
                    <ForeName>William</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stavros</LastName>
                    <ForeName>Fiona</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Coyne</LastName>
                    <ForeName>Terrance</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Swan</LastName>
                    <ForeName>Suzanne</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goddard</LastName>
                    <ForeName>Jane</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Webb</LastName>
                    <ForeName>David J</ForeName>
                    <Initials>DJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2007</Year>
                <Month>07</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Br J Clin Pharmacol</MedlineTA>
            <NlmUniqueID>7503323</NlmUniqueID>
            <ISSNLinking>0306-5251</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D065130">Endothelin A Receptor Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007555">Isoxazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D044022">Receptor, Endothelin A</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013876">Thiophenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>J9QH779MEM</RegistryNumber>
                <NameOfSubstance UI="C106276">sitaxsentan</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D065130" MajorTopicYN="Y">Endothelin A Receptor Antagonists</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007555" MajorTopicYN="N">Isoxazoles</DescriptorName>
                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007674" MajorTopicYN="N">Kidney Diseases</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008657" MajorTopicYN="N">Metabolic Clearance Rate</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044022" MajorTopicYN="N">Receptor, Endothelin A</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013876" MajorTopicYN="N">Thiophenes</DescriptorName>
                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>7</Month>
                <Day>20</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>29</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>7</Month>
                <Day>20</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17635499</ArticleId>
            <ArticleId IdType="pii">BCP2979</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1365-2125.2007.02979.x</ArticleId>
            <ArticleId IdType="pmc">PMC2198787</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Int J Clin Pract. 2006 Apr;60(4):475-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16620363</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Exp Biol Med (Maywood). 2006 Jun;231(6):653-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16740981</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Circulation. 2003 Nov 4;108(18):2184-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14597580</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nephron. 1976;16(1):31-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1244564</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cardiovasc Pharmacol. 1993;22 Suppl 8:S29-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8121179</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Am Soc Nephrol. 2006 Apr;17(4):943-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16540557</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 1994 Sep 24;344(8926):852-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7916401</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Pharmacol. 1994 Dec;113(4):1303-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7534185</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Kidney Dis. 1997 Jan;29(1):2-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9002526</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Chem. 1997 May 23;40(11):1690-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9171878</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Biophys Res Commun. 1994 Mar 30;199(3):1461-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8147891</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>